Researchers have discovered a molecular mechanism that regulates whether the cells of an aggressive colorectal cancer are conventional or inverted when they spread in the body. The discovery can help identify patients who have an elevated risk that the cancer metastasises to the abdominal cavity.
Researchers have discovered a molecular mechanism that regulates whether the cells of an aggressive colorectal cancer are conventional or inverted when they spread in the body.
(Source: Turun yliopiston viestintä/University of Turku Communications)
Turku/Finland – Researchers from the University of Turku in Finland and Gustave Roussy Institute in France have discovered a molecular mechanism that regulates whether the cells of an aggressive colorectal cancer are conventional or inverted when they spread in the body. The discovery can help identify patients who have an elevated risk that the cancer metastasises to the abdominal cavity. The study was published in the journal Nature Communications.
The researchers studied mucinous colorectal adenocarcinoma, an aggressive form of cancer that constitutes for around 10–15 percent of all colorectal cancers. It is more common in young adults and women. Unlike most colorectal cancers, mucinous colorectal adenocarcinoma spreads in the form of small, compact clusters of cells. These clusters, which are known as tumour spheres, migrate to the abdominal cavity and metastasise on the peritoneum. This dissemination pattern is associated with a poor prognosis and limited treatment options.
The tumor spheres that spread to the peritoneum are typically inverted. This is a phenomenon where the cell clusters secrete a layer of mucus onto their surface. Normally, the mucus is inside the cell cluster, in which case the cluster is considered to be conventional.
“The mucus forms a protective layer around the tumor, which reduces the effectiveness of cytostatic drugs and facilitates the spread of the cells into the abdominal cavity. This inverted structure not only helps tumor cells to migrate, but also enables them to invade tissue more effectively and makes them more resistant to chemotherapy,” says Academy Professor and Inflames research flagship group leader Johanna Ivaska from Turku Bioscience Centre at the University of Turku, Finland.
However, when the cell clusters reach the peritoneum, some of them revert to their normal state, with the mucus inside the tumor sphere. The cell cluster then attaches firmly to the surrounding tissue. This is a step that is thought to promote peritoneal metastasis. Until now, it has been unclear what triggers this reversal.
Chain reaction on a molecular level
The researchers studied tumor samples taken from patients and traced the molecular chain reaction that is triggered when tumor spheres come into contact with collagen, the structural protein of the connective tissue surrounding the tumor.
A multi-step sequence of events leads to an increase in the levels of three proteins—SorLa, Her2 and HER3—in cancer cells. The activity of these three proteins reverts the tumor cells into the conventional state and strengthens the attachment of their adhesion receptors, integrins, to the surrounding tissue.
Analysis of patient samples confirmed the pattern observed in the laboratory tests: SorLA, HER2 and HER3 levels were highest in tumor spheres in the conventional state, while in the inverted tumor spheres the levels were lower.
Possible treatment: inverting the tumor spheres
Therapeutic antibodies targeting the HER2 and HER3 receptors already exist and are used in the treatment of other cancers. The researchers therefore investigated whether these drugs might affect the inversion and adhesion of tumor cells.
“When tumor spheres grown in the laboratory were treated with antibodies, the cancer cells began to die, were inverted, and their ability to attach to the peritoneum was impaired. The results suggest a potential way of slowing the spread of cancer, but further research and clinical trials are still needed,” says Doctoral Researcher Meri Pelkonen from the University of Turku.
Colorectal cancer remains one of the world’s leading causes of cancer-related deaths, and in recent years there has been growing concern about its increasing prevalence amongst young adults. The reasons for this phenomenon are not yet fully understood. Mucinous colorectal adenocarcinoma is more prevalent in younger patients than other types of colorectal cancer, and therefore understanding its biology is particularly timely.
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.
According to the researchers, the discovered mechanism may also explain the inversion seen in other aggressive cancers and could provide a means of identifying—and, in the future, potentially treating—patients whose tumors are most likely to spread to the abdominal cavity.
The research was funded by the Cancer Foundation Finland, Research Council of Finland, Sigrid Jusélius Foundation and EU Horizon 2020.